COLL Strangle Strategy
COLL (Collegium Pharmaceutical, Inc.), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NASDAQ.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
COLL (Collegium Pharmaceutical, Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $1.13B, a trailing P/E of 14.93, a beta of 0.76 versus the broader market, a 52-week range of 28.339-50.787, average daily share volume of 542K, a public-listing history dating back to 2015, approximately 357 full-time employees. These structural characteristics shape how COLL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.76 places COLL roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on COLL?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current COLL snapshot
As of May 15, 2026, spot at $33.59, ATM IV 24.10%, IV rank 0.00%, expected move 6.91%. The strangle on COLL below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on COLL specifically: COLL IV at 24.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a COLL strangle, with a market-implied 1-standard-deviation move of approximately 6.91% (roughly $2.32 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated COLL expiries trade a higher absolute premium for lower per-day decay. Position sizing on COLL should anchor to the underlying notional of $33.59 per share and to the trader's directional view on COLL stock.
COLL strangle setup
The COLL strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With COLL near $33.59, the first option leg uses a $35.27 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed COLL chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 COLL shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $35.27 | N/A |
| Buy 1 | Put | $31.91 | N/A |
COLL strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
COLL strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on COLL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on COLL
Strangles on COLL are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the COLL chain.
COLL thesis for this strangle
The market-implied 1-standard-deviation range for COLL extends from approximately $31.27 on the downside to $35.91 on the upside. A COLL long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current COLL IV rank near 0.00% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on COLL at 24.10%. As a Healthcare name, COLL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to COLL-specific events.
COLL strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. COLL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move COLL alongside the broader basket even when COLL-specific fundamentals are unchanged. Always rebuild the position from current COLL chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on COLL?
- A strangle on COLL is the strangle strategy applied to COLL (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With COLL stock trading near $33.59, the strikes shown on this page are snapped to the nearest listed COLL chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are COLL strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the COLL strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 24.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a COLL strangle?
- The breakeven for the COLL strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current COLL market-implied 1-standard-deviation expected move is approximately 6.91%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on COLL?
- Strangles on COLL are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the COLL chain.
- How does current COLL implied volatility affect this strangle?
- COLL ATM IV is at 24.10% with IV rank near 0.00%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.